Q4 & FY22 Highlights
Dr. Lal PathLabs overview
Established consumer healthcare brand in diagnostic services
Pan-India integrated coverage with 277 clinical labs
(including National Reference Lab¹ at Delhi and Regional Ref Lab at
Kolkata), 4,731 Patient Service Centers (PSCs) and 10,599 Pick-up
Points (PUPS)²
Catalogue of 491 test panels, 2,675 pathology tests
and 1,947 radiology and cardiology tests²
Collected and processed ~65.9 mn samples from ~27.3 mn
patients in FY22; ~49.7 mn samples from ~20.3 mn patients in
FY21; ~47.7 mn samples from ~19.4 mn patients in FY20
Customers include individual patients, corporates and institutions,
healthcare providers as well as hospital and clinical labs (lab
management)
FY22: Revenue: INR 2,087.4 Cr.; EBITDA: INR 600.4 Cr³
(Margin: 28.8%); PAT: INR 350.3 Cr (Margin: 16.8%);
FY21: Revenue: INR 1,581.3 Cr.; EBITDA: INR 462.6 Cr³
(Margin: 29.3%); PAT: INR 296.5 Cr (Margin: 18.8%);
Classification: Restricted
1. Total area of 7,253 square meters
2. As on March 31, 2022.
3. Normalised EBITDA excl ESOP & CSR Cost
Accreditations
Test Menu
Routine testing
Bio-
chemistry
Specialized testing
Molecular
diagnostics
Proteomics
Hematology
Clinical pathology
Flowcytometry
Microbiology
Basic radiology
Genetics/Cytogenetics /
Genomics
Histopathology/Immunohistochemistry
and Digital Pathology and Al
Next
Generation
Sequencing
Renal Pathology and
TEM (Transmission
Electron Microscopy)
Transplant Immunology
cap
ACCREDITED™
भारत
NABL
31 Labs
ISO
ISO15189:2007
IS9001:2008
ISO27001:2013
7
Dr Lal PathLabsView entire presentation